Literature DB >> 2493436

External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis.

R L Foote1, B R Garretson, P J Schomberg, S J Buskirk, D M Robertson, J D Earle.   

Abstract

Eighteen children with retinoblastoma (25 eyes) were treated with external beam radiation at the Mayo Clinic between January 1977 and January 1987; 15 eyes were in groups I to III and 10 were in groups IV and V (Reese-Ellsworth classification). The median number of tumors per eye was 3. Radiation therapy consisted of 4- or 6-MV photons. Doses varied from 39 to 51 Gy in 1.8- to 3.0-Gy fractions. Fourteen eyes were treated through lateral fields by anterior segment-sparing techniques, and 11 eyes were treated by an anterior approach with no attempt at anterior segment sparing. All patients survived (median follow-up, 31.5 months). Cataracts developed in five eyes at a median of 23 months, four in eyes treated with anterior segment-sparing techniques. Of the 15 group I to III eyes, 6 required additional treatment; 4 were salvaged with cryotherapy or photocoagulation and 2 were enucleated. Of the 10 group IV and V eyes, 8 required additional treatment; 4 were salvaged with cryotherapy or photocoagulation, 1 with persistent disease is being followed closely, and 3 were enucleated. Ten (71%) of the 14 eyes treated with anterior segment-sparing techniques required additional treatment (9 of the 10 for tumors anterior to the equator). Four (36%) of the 11 eyes treated with an anterior approach required additional treatment (3 of the 4 for tumors in the posterior pole of group IV or V eyes). Ninety percent of the tumors 10 disc diameters or smaller (1 disc diameter = 1.6 mm) were controlled independently of dose and fractionation used when they were not in the low-dose area of the anterior retina of an eye treated with an anterior segment-sparing technique. We find that use of lateral, anterior segment-sparing techniques has a high risk of anterior retinal tumor development and cataract formation and should be abandoned in favor of techniques that treat the entire retina. A dose of 45 Gy in 1.8-Gy fractions appears to be adequate for local control of tumors smaller than 10 disc diameters. Larger tumors may require additional treatment.

Entities:  

Mesh:

Year:  1989        PMID: 2493436     DOI: 10.1016/0360-3016(89)90502-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Lens Dose-Response Prediction Modeling and Cataract Incidence in Patients With Retinoblastoma After Lens-Sparing or Whole-Eye Radiation Therapy.

Authors:  Steven M Nguyen; Julian Sison; Marjorie Jones; Jesse L Berry; Jonathan W Kim; A Linn Murphree; Vanessa Salinas; Arthur J Olch; Eric L Chang; Kenneth K Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-12-08       Impact factor: 7.038

2.  External beam radiotherapy for retinoblastoma: II. Lens sparing technique.

Authors:  N M Toma; J L Hungerford; P N Plowman; J E Kingston; D Doughty
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

3.  External beam radiotherapy for retinoblastoma: I. Whole eye technique.

Authors:  J L Hungerford; N M Toma; P N Plowman; J E Kingston
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

Review 4.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  A review of the literature for intra-arterial chemotherapy used to treat retinoblastoma.

Authors:  Emily Wyse; James T Handa; Alan D Friedman; Monica S Pearl
Journal:  Pediatr Radiol       Date:  2016-02-17

6.  Intensity modulated radiotherapy (IMRT) in bilateral retinoblastoma.

Authors:  Banu Atalar; Enis Ozyar; Kaan Gunduz; Gorkem Gungor
Journal:  Radiol Oncol       Date:  2010-09-09       Impact factor: 2.991

Review 7.  Treatment of Retinoblastoma: The Role of External Beam Radiotherapy.

Authors:  Joo-Young Kim; Younghee Park
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.